PolyPid Ltd. - Ordinary Shares (PYPD)

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / The Investor Summit Group (ISG), today announced that Ori Warshavsky, Chief Operating Officer - US Operations and Jonny Missulawin, Chief Financial Officer of PolyPid Ltd. (Nasdaq:PYPD), a late-stage biopharma company aiming to improve surgical outcomes will be presenting at this year's Investor Summit Virtual Conference on March 11th, 2025.

PolyPid Ltd. (NASDAQ: PYPD) is one of today’s top gainers. The company’s shares have moved 6.91% on the day to $3.96.

PolyPid (NASDAQ: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For more information, visit the company’s website at www.polypid.com .